Ibrutinib and indolent B-cell lymphomas

Clinical Lymphoma, Myeloma and Leukemia

Volumn 14, Issue 4, 2014, Pages 253-260

  Akinleye, Akintunde ^a,b   Furqan, Muhammad ^a   Adekunle, Oluwaseyi ^b  

^a NEW YORK MEDICAL COLLEGE   (United States)

^b Richmond University   (United States)

Author keywords

Bruton's tyrosine kinase; Chronic lymphocytic leukemia small lymphocytic lymphoma; Follicular lymphoma; Mantle cell lymphoma; Non Hodgkin lymphoma

Indexed keywords

BENDAMUSTINE; BRUTON TYROSINE KINASE; CYCLOPHOSPHAMIDE; DOXORUBICIN; IBRUTINIB; OFATUMUMAB; PLACEBO; PREDNISONE; RITUXIMAB; TEMSIROLIMUS; VINCRISTINE; AGAMMAGLOBULINAEMIA TYROSINE KINASE; ANTINEOPLASTIC AGENT; PROTEIN KINASE INHIBITOR; PROTEIN TYROSINE KINASE; PYRAZOLE DERIVATIVE; PYRIMIDINE DERIVATIVE;

ABDOMINAL PAIN; ARTHRALGIA; B CELL LYMPHOMA; BONE MARROW SUPPRESSION; BONE PAIN; CANCER CELL LINE; CANCER SURVIVAL; DIARRHEA; DRUG ACTIVITY; DRUG DOSE COMPARISON; DRUG DOSE ESCALATION; DRUG EFFICACY; DRUG MECHANISM; DRUG SAFETY; DRUG TARGETING; DRUG TOLERABILITY; DRUG WITHDRAWAL; FATIGUE; FOOD AND DRUG ADMINISTRATION; GASTROINTESTINAL HEMORRHAGE; GASTROINTESTINAL TOXICITY; HUMAN; INSOMNIA; LARGE CELL LYMPHOMA; LYMPHOPROLIFERATIVE DISEASE; MANTLE CELL LYMPHOMA; MULTIPLE CYCLE TREATMENT; MYALGIA; NAUSEA; NEUTROPENIA; PNEUMONIA; RASH; REVIEW; SEPSIS; SIGNAL TRANSDUCTION; STAPHYLOCOCCAL BACTEREMIA; THROMBOCYTOPENIA; TREATMENT PLANNING; TREATMENT RESPONSE; WALDENSTROEM MACROGLOBULINEMIA; ANIMAL; ANTAGONISTS AND INHIBITORS; CLINICAL TRIAL (TOPIC); DISEASE MODEL; DRUG SCREENING; LYMPHOMA, B-CELL; METABOLISM;

ANIMALS; ANTINEOPLASTIC AGENTS; CLINICAL TRIALS AS TOPIC; DISEASE MODELS, ANIMAL; DRUG EVALUATION, PRECLINICAL; HUMANS; LYMPHOMA, B-CELL; PROTEIN KINASE INHIBITORS; PROTEIN-TYROSINE KINASES; PYRAZOLES; PYRIMIDINES; SIGNAL TRANSDUCTION;

EID: 84904671136     PISSN: 21522650     EISSN: 21522669     Source Type: Journal    
DOI: 10.1016/j.clml.2013.11.005     Document Type: Review

References (78)

1. F. Cabanillas, S. Horning, M. Kaminski, and R. Champlin Managing indolent lymphomas in relapse: working our way through a plethora of options Hematology Am Soc Hematol Educ Program 2000 2000 166 179
2. E. Campo, S.H. Swerdlow, N.L. Harris, S. Pileri, H. Stein, and E.S. Jaffe The 2008 WHO classification of lymphoid neoplasms and beyond: evolving concepts and practical applications Blood 117 2011 5019 5032
3. R.D. Gascoyne Hematopathology approaches to diagnosis and prognosis of indolent B-cell lymphomas Hematology Am Soc Hematol Educ Program 2005 2005 299 306
4. A. Jemal, R. Siegel, and E. Ward et al. Cancer statistics, 2008 CA Cancer J Clin 58 2008 71 96
5. M.A. Lunning, and J.M. Vose Management of indolent lymphoma: where are we now and where are we going Blood Rev 26 2012 279 288
6. S.E. Herman, A.L. Gordon, and A.J. Wagner et al. Phosphatidylinositol 3-kinase-delta inhibitor CAL-101 shows promising preclinical activity in chronic lymphocytic leukemia by antagonizing intrinsic and extrinsic cellular survival signals Blood 116 2010 2078 2088
7. J.W. Friedberg, J. Sharman, and J. Sweetenham et al. Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia Blood 115 2010 2578 2585
8. L. Trentin, M. Frasson, and A. Donella-Deana et al. Geldanamycin-induced Lyn dissociation from aberrant Hsp90-stabilized cytosolic complex is an early event in apoptotic mechanisms in B-chronic lymphocytic leukemia Blood 112 2008 4665 4674
9. S.E. Herman, A.L. Gordon, and E. Hertlein et al. Bruton tyrosine kinase represents a promising therapeutic target for treatment of chronic lymphocytic leukemia and is effectively targeted by PCI-32765 Blood 117 2011 6287 6296
10. R. Küppers Mechanisms of B-cell lymphoma pathogenesis Nat Rev Cancer 5 2005 251 262
11. Y. Kawakami, J. Kitaura, and D. Hata et al. Functions of Bruton's tyrosine kinase in mast and B cells J Leukoc Biol 65 1999 286 290
12. P. Várnai, K.I. Rother, and T. Balla Phosphatidylinositol 3-kinase-dependent membrane association of the Bruton's tyrosine kinase pleckstrin homology domain visualized in single living cells J Biol Chem 274 1999 10983 10989
13. J. Rajaiya, J.C. Nixon, N. Ayers, Z.P. Desgranges, A.L. Roy, and C.F. Webb Induction of immunoglobulin heavy-chain transcription through the transcription factor Bright requires TFII-I Mol Cell Biol 26 2006 4758 4768
14. W. Liu, I. Quinto, and X. Chen et al. Direct inhibition of Bruton's tyrosine kinase by IBtk, a Btk-binding protein Nat Immunol 2 2001 939 946
15. M. Vihinen, L. Nilsson, and C.I. Smith Tec homology (TH) adjacent to the PH domain FEBS Lett 350 1994 263 265
16. S.W. Kang, M.I. Wahl, and J. Chu et al. PKCbeta modulates antigen receptor signaling via regulation of Btk membrane localization EMBO J 20 2001 5692 5702
17. B.F. Nore, P.T. Mattsson, and P. Antonsson et al. Identification of phosphorylation sites within the SH3 domains of Tec family tyrosine kinases Biochim Biophys Acta 1645 2003 123 132
18. H. Park, M.I. Wahl, and D.E. Afar et al. Regulation of Btk function by a major autophosphorylation site within the SH3 domain Immunity 4 1996 515 525
19. A.J. Mohamed, L. Vargas, B.F. Nore, C.M. Backesjo, B. Christensson, and C.I. Smith Nucleocytoplasmic shuttling of Bruton's tyrosine kinase J Biol Chem 275 2000 40614 40619
20. M. Vihinen, P.T. Mattsson, and C.I. Smith Bruton tyrosine kinase (BTK) in X-linked agammaglobulinemia (XLA) Front Biosci 5 2000 D917 D928
21. M. de Weers, M.C. Verschuren, and M.E. Kraakman et al. The Bruton's tyrosine kinase gene is expressed throughout B cell differentiation, from early precursor B cell stages preceding immunoglobulin gene rearrangement up to mature B cell stages Eur J Immunol 23 1993 3109 3114
22. A.J. Mohamed, L. Yu, and C.M. Bäckesjö et al. Bruton's tyrosine kinase (Btk): function, regulation, and transformation with special emphasis on the PH domain Immunol Rev 228 2009 58 73
23. A.B. Satterthwaite, Z. Li, and O.N. Witte Btk function in B cell development and response Semin Immunol 10 1998 309 316
24. N.J. Horwood, T.H. Page, and J.P. McDaid et al. Bruton's tyrosine kinase is required for TLR2 and TLR4-induced TNF, but not IL-6, production J Immunol 176 2006 3635 3641
25. S. Sharma, G. Orlowski, and W. Song Btk regulates B cell receptor-mediated antigen processing and presentation by controlling actin cytoskeleton dynamics in B cells J Immunol 182 2009 329 339
26. W. Yang, and S. Desiderio BAP-135, a target for Bruton's tyrosine kinase in response to B cell receptor engagement Proc Natl Acad Sci USA 94 1997 604 609
27. R. Rodriguez, M. Matsuda, and O. Perisic et al. Tyrosine residues in phospholipase Cgamma 2 essential for the enzyme function in B-cell signaling J Biol Chem 276 2001 47982 47992
28. S. Guo, G.Z. Ferl, and R. Deora et al. A phosphorylation site in Bruton's tyrosine kinase selectively regulates B cell calcium signaling efficiency by altering phospholipase C-gamma activation Proc Natl Acad Sci USA 101 2004 14180 14185
29. D. Watanabe, S. Hashimoto, and M. Ishiai et al. Four tyrosine residues in phospholipase C-gamma 2, identified as Btk-dependent phosphorylation sites, are required for B cell antigen receptor-coupled calcium signaling J Biol Chem 276 2001 38595 38601
30. P. Antony, J.B. Petro, G. Carlesso, N.P. Shinners, J. Lowe, and W.N. Khan B-cell antigen receptor activates transcription factors NFAT (nuclear factor of activated T-cells) and NF-kappaB (nuclear factor kappaB) via a mechanism that involves diacylglycerol Biochem Soc Trans 32 2004 113 115
31. S.L. Doyle, C.A. Jefferies, C. Feighery, and L.A. O'Neill Signaling by Toll-like receptors 8 and 9 requires Bruton's tyrosine kinase J Biol Chem 282 2007 36953 36960
32. F.M. Uckun Bruton's tyrosine kinase (BTK) as a dual-function regulator of apoptosis Biochem Pharmacol 56 1998 683 691
33. T. Yamadori, Y. Baba, and M. Matsushita et al. Bruton's tyrosine kinase activity is negatively regulated by Sab, the Btk-SH3 domain-binding protein Proc Natl Acad Sci USA 96 1999 6341 6346
34. L. Yu, A.J. Mohamed, and L. Vargas et al. Regulation of Bruton tyrosine kinase by the peptidylprolyl isomerase Pin1 J Biol Chem 281 2006 18201 18207
35. S. Tsukada, D.C. Saffran, and D.J. Rawlings et al. Deficient expression of a B cell cytoplasmic tyrosine kinase in human X-linked agammaglobulinemia Cell 72 1993 279 290
36. D. Vetrie, I. Vorechovský, and P. Sideras et al. The gene involved in X-linked agammaglobulinaemia is a member of the src family of protein-tyrosine kinases Nature 361 1993 226 233
37. R. Kersseboom, S. Middendorp, and G.M. Dingjan et al. Bruton's tyrosine kinase cooperates with the B cell linker protein SLP-65 as a tumor suppressor in Pre-B cells J Exp Med 198 2003 91 98
38. A. Vassilev, Z. Ozer, C. Navara, S. Mahajan, and F.M. Uckun Bruton's tyrosine kinase as an inhibitor of the Fas/CD95 death-inducing signaling complex J Biol Chem 274 1999 1646 1656
39. J.J. Buggy, and L. Elias Bruton tyrosine kinase (BTK) and its role in B-cell malignancy Int Rev Immunol 31 2012 119 132
40. M. Gururajan, C.D. Jennings, and S. Bondada Cutting edge: constitutive B cell receptor signaling is critical for basal growth of B lymphoma J Immunol 176 2006 5715 5719
41. R.E. Davis, V.N. Ngo, and G. Lenz et al. Chronic active B-cell-receptor signalling in diffuse large B-cell lymphoma Nature 463 2010 88 92
42. P.A. Goodman, C.M. Wood, A.O. Vassilev, C. Mao, and F.M. Uckun Defective expression of Bruton's tyrosine kinase in acute lymphoblastic leukemia Leuk Lymphoma 44 2003 1011 1018
43. L.P. Kil, M.J. de Bruijn, J.A. van Hulst, A.W. Langerak, S. Yuvaraj, and R.W. Hendriks Bruton's tyrosine kinase mediated signaling enhances leukemogenesis in a mouse model for chronic lymphocytic leukemia Am J Blood Res 3 2013 71 83
44. L.A. Brosens, K.M. Tytgat, and F.H. Morsink et al. Multiple colorectal neoplasms in X-linked agammaglobulinemia Clin Gastroenterol Hepatol 6 2008 115 119
45. J. Hutcheson, K. Vanarsa, and A. Bashmakov et al. Modulating proximal cell signaling by targeting Btk ameliorates humoral autoimmunity and end-organ disease in murine lupus Arthritis Res Ther 14 2012 R243
46. J.A. Burger, and J.J. Buggy Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) Leuk Lymphoma 54 2013 2385 2391
47. E.M. Ruderman, and R.M. Pope More than just B-cell inhibition Arthritis Res Ther 13 2011 125
48. M. Wu, A. Akinleye, and X. Zhu Novel agents for chronic lymphocytic leukemia J Hematol Oncol 6 2013 36
49. Z. Pan, H. Scheerens, and S.J. Li et al. Discovery of selective irreversible inhibitors for Bruton's tyrosine kinase ChemMedChem 2 2007 58 61
50. L.A. Honigberg, A.M. Smith, and M. Sirisawad et al. The Bruton tyrosine kinase inhibitor PCI-32765 blocks B-cell activation and is efficacious in models of autoimmune disease and B-cell malignancy Proc Natl Acad Sci USA 107 2010 13075 13080
51. M. Cinar, F. Hamedani, Z. Mo, B. Cinar, H.M. Amin, and S. Alkan Bruton tyrosine kinase is commonly overexpressed in mantle cell lymphoma and its attenuation by Ibrutinib induces apoptosis Leuk Res 37 2013 1271 1277
52. E. Sahakian, J. Rock-Klotz, and B.D. Shah et al. Combination of ACY1215, a selective histone deacetylase 6 (HDAC6) inhibitor with the bruton tyrosine kinase (BTK) inhibitor, ibrutinib, represents a novel therapeutic strategy in mantle cell lymphoma (MCL) Blood (ASH Annu Meet Abstr) 120 2012 abstract 1660
53. S. Ponader, S.S. Chen, and J.J. Buggy et al. The Bruton tyrosine kinase inhibitor PCI-32765 thwarts chronic lymphocytic leukemia cell survival and tissue homing in vitro and in vivo Blood 119 2012 1182 1189
54. Y.L. Wang, S. Cheng, and J. Ma et al. BTK Inhibition Targets in Vivo CLL Proliferation Through Its Effects On B-Cell Receptor Signaling Activity Blood (ASH Annu Meet Abstr) 120 2012 abstract 2903
55. M.F. de Rooij, A. Kuil, and C.R. Geest et al. The clinically active BTK inhibitor PCI-32765 targets B-cell receptor- and chemokine-controlled adhesion and migration in chronic lymphocytic leukemia Blood 119 2012 2590 2594
56. J.A. Dubovsky, K.A. Beckwith, and G. Natarajan et al. Ibrutinib is an irreversible molecular inhibitor of ITK driving a Th1-selective pressure in T lymphocytes Blood 122 2013 2539 2549
57. PollyeaD, S. Smith, and N. Fowler et al. A phase I dose escalation study of the Btk inhibitor PCI-32765 in relapsed and refractory B cell non-Hodgkin lymphoma and use of a novel fluorescent probe pharmacodynamic assay Blood 114 2009 abstract 3713
58. R.H. Advani, J.J. Buggy, and J.P. Sharman et al. Bruton tyrosine kinase inhibitor ibrutinib (PCI-32765) has significant activity in patients with relapsed/refractory B-cell malignancies J Clin Oncol 31 2013 88 94
59. M.J. Keating, I. Flinn, and V. Jain et al. Therapeutic role of alemtuzumab (Campath-1H) in patients who have failed fludarabine: results of a large international study Blood 99 2002 3554 3561
60. S.J. Lemery et al. U.S. Food and Drug Administration approval: ofatumumab for the treatment of patients with chronic lymphocytic leukemia refractory to fludarabine and alemtuzumab Clin Cancer Res 16 17 2010 4331 4338
61. J.C. Byrd, R.R. Furman, and S.E. Coutre et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia N Engl J Med 369 2013 32 42
62. J.C. Byrd, J.C. Barrientos, and S. Devereaux et al. A randomized, multicenter, open-label, phase III study of the Bruton tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) versus ofatumumab in patients (pts) with relapsed or refractory (RR) chronic lymphocytic leukemia (CLL)/small lymphocytic lymphoma (SLL): RESONATE J Clin Oncol 31 suppl 2013 abstract TPS8619
63. J. Byrd, R.R. Furman, and S. Coutre et al. The Bruton's tyrosine kinase (BTK) inhibitor ibrutinib (PCI-32765) promotes high response rate, durable remissions, and is tolerable in treatment naïve (TN) and relapsed or refractory (RR) chronic lymphocytic leukemia (CLL) or small lymphocytic lymphoma (SLL) patients including patients with high-risk (HR) disease: new and updated results of 116 patients in a phase Ib/II study Blood (ASH Annu Meet Abstr) 120 2012 abstract 189
64. J. Burger, P. Ghia, and A. Polliack et al. Randomized, multicenter, open-label, phase III study of the BTK inhibitor ibrutinib versus chlorambucil in patients 65 years or older with treatment-naive CLL/SLL (RESONATE-2, PCYC-1115-CA) J Clin Oncol 31 suppl 2013 abstract TPS7130
65. B. Chang, R.R. Furman, and M. Zapatka et al. Use of tumor genomic profiling to reveal mechanisms of resistance to the BTK inhibitor ibrutinib in chronic lymphocytic leukemia (CLL) J Clin Oncol 31 suppl 2013 abstract 7014
66. J. Burger, W. Wierda, and J. Hoellenriegel et al. The BTK inhibitor ibrutinib (PCI-32765) in combination with rituximab is well tolerated and displays profound activity in high-risk chronic lymphocytic leukemia (CLL) patients Blood (ASH Annu Meet Abstr) 120 2012 abstract 187
67. K. Fischer, P. Cramer, and R. Busch et al. Bendamustine combined with rituximab in patients with relapsed and/or refractory chronic lymphocytic leukemia: a multicenter phase II trial of the German Chronic Lymphocytic Leukemia Study Group J Clin Oncol 29 2011 3559 3566
68. M.A. Bergmann, M.E. Goebeler, and M. Herold et al. Efficacy of bendamustine in patients with relapsed or refractory chronic lymphocytic leukemia: results of a phase I/II study of the German CLL Study Group Haematologica 90 2005 1357 1364
69. J. Brown et al. Combination of the Bruton's tyrosine kinase inhibitor PCI-32765 with bendamustine/rituximab (BR) in patients with relapsed/refractory chronic lymphocytic leukemia: Interim results of a phase Ib/II study EHA Meet 2012 abstract 1590
70. S.M. Jaglowski, J.A. Jones, and J.M. Flynn et al. A phase Ib/II study evaluating activity and tolerability of BTK inhibitor PCI-32765 and ofatumumab in patients with chronic lymphocytic leukemia/small lymphocytic lymphoma (CLL/SLL) and related diseases J Clin Oncol 2012 abstract 6508
71. N. Fowler, R.H. Advani, and J. Sharman et al. The Bruton's tyrosine kinase inhibitor ibrutinib (PCI-32765) is active and tolerated in relapsed follicular lymphoma Blood (ASH Annu Meet Abstr) 120 2012 abstract 156
72. G. Salles, A.K. Gopal, and P. Martin et al. An open-label phase II study of ibrutinib in patients with refractory follicular lymphoma J Clin Oncol 31 suppl 2013 abstract TPS8614
73. M.L. Wang, S. Rule, and P. Martin et al. Targeting BTK with ibrutinib in relapsed or refractory mantle-cell lymphoma N Engl J Med 369 2013 507 516
74. R.C. Kane, R. Dagher, and A. Farrell et al. Bortezomib for the treatment of mantle cell lymphoma Clin Cancer Res 13 2007 5291 5294
75. A. Goy, R. Sinha, and M.E. Williams et al. Single-agent lenalidomide in patients with mantle-cell lymphoma who relapsed or progressed after or were refractory to bortezomib: phase II MCL-001 (EMERGE) study J Clin Oncol 31 2013 3688 3695
76. K. Blum, B. Christian, and J.M. Flynn et al. A phase I trial of the Bruton's tyrosine kinase (BTK) inhibitor, ibrutinib (PCI-32765), in combination with rituximab (R) and bendamustine in patients with relapsed/refractory non-Hodgkin's lymphoma (NHL) Blood (ASH Annu Meet Abstr) 120 2012 abstract 1643
77. M. Wang, L.I. Gordon, and S. Rule et al. A phase III study of ibrutinib in combination with bendamustine and rituximab (BR) in elderly patients with newly diagnosed mantle cell lymphoma (MCL) J Clin Oncol 31 suppl 2013 abstract TPS8613
78. A. Younes, I. FLinn, and J.G. Berdeja et al. Phase Ib study combining ibrutinib with rituximab, cyclophosphamide, doxorubicin, vincristine, and prednisone (R-CHOP) in patients with CD20-positive B-cell non-Hodgkin lymphoma (NHL) J Clin Oncol 31 suppl 2013 abstract 8502